CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours

NCT06986811

Status	RECRUITING
Phase	Phase 2
Sponsor	CEBIOTEX
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (16)

- To be eligible to participate in this trial, an individual must meet all the following criteria:
- d 18 years.
- Participants must have a diagnosis of:
- De novo or recurrent abdominal soft-tissue sarcoma.
- De novo or recurrent high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification, regardless of response to frontline therapy, diagnosed either by a former histologic verification of neuroblastoma and/or former demonstration of tumour cells in the bone marrow with increased urinary catecholamines at the time of study enrolment. Participants who were initially considered low or intermediate risk but were then reclassified as high risk are also eligible.

... and 11 more (see full listing online)

Exclusion (15)

- An individual who meets any of the following criteria will be excluded from participation in this trial:
- Metastatic lesions.
- Other malignancies within past 2 years except for in-situ cancers or basal/squamous cell skin cancer. Subjects with other malignancies are eligible if they are disease-free for at least 24 months or have a clinically stable concurrent malignancy not requiring tumour-directed treatment.
- Active bacterial, viral or fungal infection.
- Known history of active human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C or chronic liver disease. Testing is not required in the absence of clinical findings or suspicion.

... and 10 more (see full listing online)

Locations (1 total)

Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain